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EBV infected cells (Figure 1 ). Complete remission was obtained after chemotherapy with cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisolone (CHOP). However, the patient died of recurrence of lymphoma 8 months after admission.
ALCL is essentially defined by features including proliferation of large lymphoid cells with strong expression of CD30 (Ki-1) antigen, which was reported by Schwab et al 1 to be specific to Hodgkin cells and Reed-Sternberg cells. ALCL is now widely recognized to have a broad morphologic and phenotypic spectrum. It is closely associated with the expression of chimeric NPM-ALK protein activated by the (2;5)(p23;q35) chromosomal translocation. NPM/ALK-positive ALCL represents a distinct genetic entity that occurs in young patients, has a favorable prognosis, and should be differentiated from the NPM/ALKnegative tumors including ATLL, which have a relatively aggressive clinical course. It has been reported that monoclonal integration of HTLV-I proviral DNA was detected in 39.5% of cases of CD30 (Ki-1)-positive ALCL in an HTLV-I endemic area. 2 Most of the ALCL patients with HTLV-I proviral DNA exhibited frequent lymphadenopathy and extranodal large tumor or nodules, but a few exhibited leukemic changes, bone marrow involvement, and hypercalcemia. The latter patients had a very poor prognosis despite immediate performance of chemotherapy. Some of these clinical features differ from those of ATLL. These results suggest that ALCL with HTLV-I proviral DNA may be a unique histologic subgroup of ATLL. The relationship between ALCL and HTLV-I infection has not been clarified. CD30 (Ki-1) antigen, an activated T cell antigen, is a member of the tumor necrosis factor/nerve cell growth factor receptor super-family. The pX region of HTLV-I, which has been shown to encode for the transacting regulator gene (tax and rex), might play an important role in expression of CD30 antigen. T cell markers of CD2, CD4, and/or CD3 were expressed in 88.2% of cases of ALCL with HTLV-I proviral DNA. 2 In the present case, T cell markers (CD2, CD3, CD4, CD5, and CD8) were not expressed. The incidence of double-negative (CD4 − /CD8 − ) ATL was 7%, 3 while it has been reported that lack of CD2, CD3, and CD5 antigens worsens prognosis. Furthermore, the lymphoma cells of the presented case had a clonal EBV genome. 
TO THE EDITOR
The t(17;19)(q21-q22;p13) is a recurring chromosomal translocation that is rarely found in B-lineage acute lymphoblastic leukemia (ALL) of childhood. 1 This translocation results in the in frame fusion of the 5′-region of the E2A gene on chromosome 19 and the 3′-region of the HLF gene on chromosome 17. Its product, E2A-HLF chimeric protein, is responsible for the pathogenesis of t(17;19)-ALL in that it inhibits lymphoid precursor cells from undergoing apoptosis. 2, 3 This paper reports the establishment of a new B-lineage cell line with t(17;19), YCUB-2, which expresses two different types of E2A-HLF fusion proteins.
This cell line, established in 1997, was derived from a peripheral blood sample taken from a 4-year-old Japanese boy with ALL carrying Chromosomal analysis showed 46,XY,t(17;19)(q22;p13.3). The patient suffered from hypercalcemia due to overproduction of parathyroid hormone-related protein in the leukemic cells. There was no evidence of disseminated intravascular coagulation (DIC). Although complete remission was achieved with chemotherapy, he relapsed 5 months later and died of progressive disease. The leukemic cells isolated from a peripheral blood sample obtained at the time of refractory disease, were cultured in RPMI1640 medium supplemented with 10% fetal calf serum for over 12 months, and the established cell line, YCUB-2, was isolated and characterized.
YCUB-2 expressed CD10, CD19, CD20, CD33, and HLA-DR antigens as well as the patient's leukemic cells. CD2, CD3, CD4, CD7, and CD8 as T-lineage markers and CD13 and CD14 as myeloid markers were not expressed. CD34 and surface immunoglobulin were also not expressed. The chromosomal analysis showed the same karyotype as original leukemic cells. The doubling time of YCUB-2 was about 24-26 h. Reverse transcription-polymerase chain reaction (RT-PCR) using a primer pair with a 20-bp sequence in E2A exon 12 as the
Figure 1
RT-PCR analysis of E2A-HLF fusion transcripts. One hundred nanograms of total RNA extracted from YCUB-2 was reverse transcribed, sequentially diluted to 10 0 to 10 −6 with cDNA obtained from normal human lymphocyte, and then subjected to RT-PCR using a sense primer located in E2A exon 12 and an antisense primer located in HLF exon 4 (lanes 2 to 8, respectively). Lane 1, molecular weight marker (X174/HinfI).
sense primer and a 20-bp sequence in HLF exon 4 as the antisense primer, detected three kinds of transcripts of different lengths (denoted as transcript A, B, and C, according to size) ( Figure 1, lane 2) . The nucleotide sequence of these transcripts revealed that in transcripts A and B, E2A was truncated at the middle of exon 13 and fused to HLF exon 4, intercalated with a 137-bp or 90-bp nucleotide sequence, respectively, of unknown origin. In transcript C, the 3′ end of E2A exon 12 was directly fused to the 5′ end of HLF exon 4 ( Figure 2 ). Transcripts B and C were each rearranged in frame between the E2A and HLF genes, and the size of their products was calculated to be 56 kDa and 52 kDa, respectively. In transcript A, there was a frame shift between these genes, which generated a stop codon in the HLF region and yielded a 52 kDa protein.
To detect the expression of the E2A-HLF fusion proteins, cell extracts of YCUB-2 were immunoprecipitated with anti-E2A antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) or anti-HLF antibody (Oncogene Research Products, Cambridge, MA, USA), followed by immunoblotting with anti-HLF antibody. Two immunoreactive bands were detected at 56 kDa and 52 kDa, which were derived from transcript B and transcript C, respectively (data not shown). The protein derived from transcript A was not detected by Western blot analysis using anti-E2A antibody (data not shown). This result may be explained as follows. The products of transcript A and transcript C could not be separated on sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE), because either the molecular weight of the protein derived from transcript A was similar to that from transcript C (nearly 52 kDa), or the level of expression of transcript A was 10-to 100-fold lower than that of transcript B or transcript C as examined by the limited dilution method (Figure 1, lanes 2-8) .
It has been reported that t(17;19) produces two types of E2A-HLF fusion mRNA, type I and type II. 1, 4, 5 The type I transcript results from genomic rearrangement between E2A intron 13 and HLF intron 3. The rearranged DNA is spliced into mRNA to maintain an open reading frame that encodes a functional E2A-HLF fusion protein. This mRNA carries a cryptic exon that consists of the E2A intronic sequence at the 5′ end, untemplated sequence in the middle, and the HLF intronic sequence at the 3′ end. In the type II transcript, the 3′ end of E2A exon 12 is directly fused in frame to the 5′ end of HLF exon 4.
Three types of transcripts of E2A-HLF, transcripts A, B, and C, were found in YCUB-2 as well as in the patient's leukemic cells. Because these transcripts could be detected in colonies that emerged from single cell in soft agar culture, they are generated by alternative splicing of the E2A-HLF fusion gene, and not by different cell clones. According to the cDNA sequences, transcripts A and B belong to type I and transcript C belongs to type II transcripts. However, the structures of transcripts A and B considerably differ from that of the type I transcripts previously described. 1 In comparison with the type I transcripts previously reported, transcripts A and B lack 124 nucleotides in the 3′ region of E2A exon 13; contain 137-bp or 90-bp, respectively, of intervening sequence of unknown origin; and do not contain nucleotides from intron 13 of E2A and intron 3 of HLF. Since no sequence homologous to either of the two intervening sequences could be found on a search in Genbank, these intervening sequences were newly acquired untemplatedly. Since transcript A cannot generate a full-length, functional protein and since its expression was much lower than the expression of transcripts B and C, this gene product may not play an important role in the process of leukemogenesis in t(17;19) ALL.
When the type I and type II E2A-HLF fusion proteins were compared in an in vitro assay, there was no difference in the DNA-binding activities but there was a slight difference in the transcriptional activation properties. 6 This may explain the distinct clinical differences between patients with the two types of t(17;19) ALL. For example, DIC develops more frequently among those with type I t(17;19) ALL than among those with type II t(17;19) ALL. A previously reported case with t(17;19) expressed both types of fusion E2A-HLF transcripts simultaneously. 4 In that case, dual expression was detected at presentation and at relapse, whereas only type II transcripts were detected during cytological complete remission. This suggests that type I transcripts of E2A-HLF play a more significant role(s) than type II transcripts in the progression of leukemia.
Before our report, only two cell lines, HAL-01 and UoC-B1, derived from t(17;19) leukemia have been reported, and both expressed only type I fusion proteins of E2A-HLF. 7, 8 Thus, the YCUB-2 line is useful for investigating leukemogenesis through E2A-HLF type II fusion proteins and the interaction between two types of fusion proteins.
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Do transcriptionally silent BCR-ABL cells persist in CML patients in molecular remission after stem cell transplantation?
TO THE EDITOR
The only current curative treatment for chronic myeloid leukemia (CML) is allogeneic stem cell transplantation (SCT). However, relapses occur in 10-30% of patients transplanted in chronic phase and even more frequently in patients transplanted in later phases of CML. As relapses can appear after long-term molecular remissions detected by nested RT-PCR for BCR-ABL transcript, the question arises of what is the origin of cells whose activation results in a relapse. A rational explanation seems to be the persistence of cells with an unexpressed BCR-ABL gene. The question of existence of such transcriptionally silent BCR-ABL cells was addressed by several authors with contradictory conclusions. Zhang et al, 1 when comparing the results of genomic DNA PCR for BCR-ABL with RT-PCR, found that CML patients in remission after SCT do not generally harbor a substantial pool of transcriptionally silent BCR-ABL cells. On the other hand, Chomel et al negative or only weakly positive (BCR-ABL/ABL close to 0.002%). In two patients with a sex-mismatched donor, the level of cells with the BCR-ABL genomic rearrangement was also confirmed by FISH using X and Y chromosome probes. The detected amount of quiescent cells is surprisingly high, particularly in patients after SCT (3-11%). This finding does not correspond with the results of the above authors 1 and also with our own experience.
Our considerations result from the comparison of hematopoietic mixed chimerism analyses based on genomic DNA PCR for a variable number of tandem repeat (VNTR) sequences, and the level of BCR-ABL transcripts in peripheral blood samples from patients with CML after SCT. The chimerism analyses can identify the proportion of recipient and donor blood cells in post-SCT patients but do not distinguish between leukemic and normal recipient cells. However, the number of host cells clearly determines the highest possible number of leukemic cells while, on the other hand, the absence of host cell DNA unambiguously excludes the presence of leukemic cells with BCR-ABL genomic rearrangement of host cell origin at the sensitivity level of the method. The sensitivity of PCR for various VNTR loci, assessed by dilution of recipient cells into donor cells, was found to be 5-0.8% for ApoBII, Col2A1, YNZ22, HVR-Ig and TPO loci (higher sensitivity for short recipient alleles); 0.5% using D1S80 and MCT118 locus; 0.1-0.01% for AMG sex specific locus and 0.1-0.01% in 1st PCR and 0.001-0.0001% in 2nd PCR of two-step nested PCR for the sex-specific locus DYZ1 in female-male donor-recipient pairs. 3 The presence and amount of the BCR-ABL transcripts were detected by qualitative and quantitative competitive two-step RT-PCR with a sensitivity of 0.001-0.0001% (10 ). 4 
